Morgan Stanley Issues Positive Forecast for argenex (NASDAQ:ARGX) Stock Price

argenex (NASDAQ:ARGX) had its price target hoisted by equities research analysts at Morgan Stanley from $1,140.00 to $1,190.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price objective indicates a potential upside of 35.80% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. Oppenheimer reduced their target price on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a research report on Monday, October 12th. Royal Bank Of Canada dropped their price objective on shares of argenex from $1,100.00 to $1,025.00 and set an “outperform” rating for the company in a research note on Tuesday. Barclays reiterated a “buy” rating on shares of argenex in a report on Monday, September 7th. UBS Group raised shares of argenex from a “neutral” rating to a “buy” rating and raised their target price for the stock from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Finally, DZ Bank restated a “buy” rating on shares of argenex in a research report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,142.37.

argenex Stock Up 0.1%

Shares of argenex stock traded up $0.55 during mid-day trading on Friday, reaching $876.31. 184,860 shares of the stock traded hands, compared to its average volume of 352,220. The business has a 50-day moving average of $956.17 and a 200 day moving average of $885.45. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The stock has a market capitalization of $55.11 billion, a PE ratio of 33.69, a PEG ratio of 0.82 and a beta of 0.44.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a return on equity of 43.59% and a net margin of 32.19%. On average, equities research analysts expect that argenex will post 28.71 EPS for the current fiscal year.

Hedge Funds Weigh In On argenex

A number of institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after purchasing an additional 83,568 shares during the last quarter. Jennison Associates LLC lifted its holdings in argenex by 3.4% in the first quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after acquiring an additional 7,707 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in argenex by 1.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock worth $130,277,000 after acquiring an additional 2,579 shares during the period. First Trust Advisors LP grew its position in argenex by 98.9% in the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after acquiring an additional 53,293 shares during the period. Finally, Eagle Health Investments LP increased its stake in argenex by 21.7% during the first quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock worth $55,744,000 after acquiring an additional 13,606 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong Q3 performance: argenx reported $1.75 billion in revenue and $7.80 in earnings per share, exceeding the $7.44 consensus estimate. Product net sales rose 54% year over year to $1.7 billion, while operating profit reached $486 million, supporting the investment case. argenx quarterly earnings report
• Positive Sentiment: Analysts remain constructive: Guggenheim lowered its price target to $1,120 from $1,185 but retained a “buy” rating. Wells Fargo cut its target to $1,336 from $1,356 while maintaining an “overweight” rating. Both targets imply meaningful upside from current levels. Guggenheim analyst rating Wells Fargo analyst rating
• Positive Sentiment: Potential entry point: Jefferies described the post-Sjogren’s reaction as a potential buying opportunity and said it continues to like ARGX’s setup through year-end 2026. Jefferies comments on argenx
• Neutral Sentiment: Robert W. Baird raised its target to $861 from $823 but maintained a “neutral” rating, suggesting limited upside at its valuation. Baird analyst rating
• Negative Sentiment: Clinical setback: A surprise testing setback in Sjogren’s syndrome involving efgartigimod, argenx’s core product, raised concerns about future growth and helped offset the earnings beat. Royal Bank of Canada also reduced its price target, adding to near-term caution. argenx clinical testing setback

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.